GrayMatters Health’s Post

At the Centre of Clinical Excellence, we’re committed to transforming care for those who served. BrainStim Health, an affiliate of the CCE, is launching a new clinical trial featuring the Magstim Horizon 3.0. The trial will explore the use of non-invasive TMS therapy to address the complex health needs of Veterans. This research-driven project aims to evaluate the effectiveness of non-invasive brain stimulation therapy in: - Reducing chronic pain and PTSD symptoms - Improving outcomes for Veterans with depression - Treating symptoms related to mild traumatic brain injuries (mTBI) and concussions - Providing insights into the potential of rTMS to treat comorbid conditions For more information, visit https://lnkd.in/gRAbzfHA

As the FDA considers MDMA-Assisted Therapy for PTSD, it's crucial to hear from clinical trial participants like myself. Having experienced both the placebo and MDMA trial, I can attest to the profound impact of this combined therapy on unwinding complex trauma. The neurological benefits of pausing the fight/flight response are well-documented, underlining the therapeutic potential of this approach. I compare the last 40 years of therapeutic experience to this therapy. I had never used MDMA before this trial. I went through a placebo and then the MDMA trial. I cannot explain what happens if false victims use this therapy, or why the trial design was deemed suitable by the FDA and then not suitable. What I can explain is that this combined therapy unwound complex trauma that no other medical compound or therapy could unwind. The experience of meeting my therapists with a newfound self-agency to help them help me was profound. The neurological impact of pausing the fight/flight response is well-understood as evidenced by multiple studies. The bottom line is that I would counsel my loved ones to try this over any other prescribed medication - especially as proposed as a dual therapy (with a therapist guiding individuals through the medication). In a landscape where profit-driven medications can worsen symptoms and increase suicidality, a shift towards more effective and holistic therapies is essential. It's time for a paradigm shift towards treatments that prioritize patient well-being and long-term healing. We deserve better than the current 'try it and see if it works' mentality. #PTSD #ClinicalTrials #MentalHealthAwareness #MDMA4PTSD

Day 1 of the 2024 DCNP Certification Review Course was a success! We tackled Neoplasms, Adnexal Disorders, and Psychodermatoses. Get ready for even more in-depth learning tomorrow! 💪📚 Day 2 Course Review dives into Papulosquamous Disorders, Psoriasis and more! Those attending the Workshops will gain practical insights for all. #2024SDNPConference #SDNPKiawah2024 #CertificationMatters #DCNP #ReviewCourse #ContinuingEducation #CoreComptencies

See these important results from: Meta-analysis was based on four studies (one single-blinded trial and three open label trials, 63 patients total before treatment, 38 after eight weeks). Valproate was associated with a statistically significant reduction in PTSD symptoms at eight weeks compared to baseline, Hedge’s g -0.982 (95% CI: -1.499 to -0.465 using random-effects model), and a significant reduction in depression from baseline, Hedge’s g -0.775 (95% CI: -1.274 to -0.276 using random-effects model). No significant heterogeneity was found for either analysis (p=0.274 for PTSD and p=0.286 for depression). Results for fixed-effect models were similar.

There is an urgent need to use data-driven approaches to better characterize complex psychiatric presentations with the aim of improving treatment outcomes. We sought to determine if machine learning models could predict PTSD-related illness in a real-world treatment-seeking population using self-report clinical data. Machine learning models accurately predicted trauma symptom severity and functional impairment scores in a masked subset of data, consisting of a sample of adults seeking inpatient treatment for PTSD. Homewood Research Institute (HRI) The Trauma & Recovery Research Unit Check out our work at https://lnkd.in/g2TUwfw6

Unlock the Full Picture of TMD: Beyond the Jaw – A Webinar with Dr. Greenbaum Temporomandibular disorders (TMD) are far more than just jaw issues—it's a complex condition that involves the head, neck, and mandible. In this insightful introductory webinar, renowned TMD expert Dr. Greenbaum will guide you through the essentials of understanding TMD, including its causes, symptoms, and the vital connection between neck function and TMD. We'll explore the latest research, assessment techniques, and treatment approaches, offering a broad understanding of this often-misunderstood disorder. You’ll come away with a new perspective on how therapists can make a significant difference for patients who are frequently left untreated. This webinar will provide a solid foundation, but it’s just the start! Dive deeper with our full course to uncover the vast potential you have to transform the lives of those suffering from TMD. Join us and take the first step in mastering the bigger picture of TMD care!

Unlock the Full Picture of TMD: Beyond the Jaw – A Webinar with Dr. Greenbaum Temporomandibular disorders (TMD) are far more than just jaw issues—it's a complex condition that involves the head, neck, and mandible. In this insightful introductory webinar, renowned TMD expert Dr. Greenbaum will guide you through the essentials of understanding TMD, including its causes, symptoms, and the vital connection between neck function and TMD. We'll explore the latest research, assessment techniques, and treatment approaches, offering a broad understanding of this often-misunderstood disorder. You’ll come away with a new perspective on how therapists can make a significant difference for patients who are frequently left untreated. This webinar will provide a solid foundation, but it’s just the start! Dive deeper with our full course to uncover the vast potential you have to transform the lives of those suffering from TMD. Join us and take the first step in mastering the bigger picture of TMD care!

Following the Spark: Actionable strategies to untangle the complexities of neurodevelopmental disorders This free webinar series, presented by the Physician Learning Program and the University of Alberta, will address the topics of #autism, neurodevelopmental and rare disorders like fragile X syndrome. Each session will be framed within the context of case-based discussions with particular emphasis on identifying strategies, theoretical knowledge, and actionable recommendations. March 7: Navigating unique care needs across the lifespan: Perspectives in adult care and First Nations families March 14: Panel discussion: Supporting individuals, families and care providers https://ow.ly/St8u50QNSJX

There is still time to register for the March 14: Panel discussion: Supporting individuals, families and care providers!!

Huge disappointment with the FDA issuing a CRL on MDMA-AT. Why is that? Is it because we’re hoping for a new era ushered in by MDMA AT. Or Because we need more treatment options to help people living with PTSD. If #1, then I guess this will have to wait. If #2, then as Owen Muir MD DFAACAP as well as Richard Bermudes, M.D. pointed out, there are a few other treatments available though not widely used. The last one cleared by FDA in 2023 for the treatment of PTSD is Prism for PTSD – a neuroscience based, easy to use medical device that has been shown to be safe and effective for patients: -         Neuroscience - It uses an amygdala-based biomarker. -         No drugs - Unlike #MDMA aka #midomafetamine, it is not drug based. -         Easy to get started – Training requires about 4 hours long. -         It is accessible - It requires guidance by a healthcare professional, but far less than the time required for MDMA AT. -         It is personal - As patients use Prism, they stand to discover the ultimate personal treatment, giving them a tool for controlling PTSD symptoms in everyday life. -         Safe - Side effects in clinical studies were mild and temporary, such as headaches, nausea, and fatigue. So, if you are a healthcare provider helping people who are living with  trauma, contact me or Kirk Thelander or anyone else on the GrayMatters Health team. Now it is on us to make Prism widely available so more people living with the aftermath of #trauma can get back to better. PS. I am thankful for the public discussion around MDMA. It raised awareness for trauma and #PTSD, and it brought to light various aspects of what is in the best interests of the patient. PPS. I often see statements like “[patients] have not seen any new treatment options in over two decades”. This is not true. Enough. American Psychiatric Association NAMI